


STANDARD OPERATING PROCEDURE

Handling, Maintenance and Quality Control of the GH3 cell line, version 2.0

EURL ECVAM validation study of a battery of mechanistic methods relevant for the detection of chemicals that can disrupt the thyroid hormone system





Joint Research Centre This Standard Operating Procedure (SOP) has been prepared within the context of a collaboration agreement with the Joint Research Centre (JRC) Directorate for Health, Consumers and Reference Materials (Chemicals Safety and Alternative Methods Unit F3 / EURL ECVAM), for the validation of mechanistic methods to identify potential modulators of thyroid hormone signalling. It aims to provide evidence-based scientific support to the European policymaking process. The contents of this publication do not necessarily reflect the position or opinion of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. The designations employed and the presentation of material on the maps do not imply the expression of any opinion whatsoever on the part of the European Union concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

This SOP is part of a series of 3 SOPs used to perform the "T-screen assay measuring cell proliferation of GH3 cells using alamar blue/ resazurin":

- 1. SOP "T-screen assay measuring cell proliferation of GH3 cells using alamar blue/resazurin" v2.0 (used in Part 2 of the validation study)
- 2. **SOP "Handling, Maintenance and Quality Control of the GH3 cell line " v2.0** (used in Part 2 of the validation study)
- 3. SOP "Determination of cell proliferation in T screen assay" v2.0 (used in Part 2 of the validation study)

The method was developed by Arno Gutleb, LIST (Luxembourg) and subsequently implemented by the EU-NETVAL test facility NIOM (Poland) within the validation study. For the purpose of running the method on a robotic platform during part 2 of the validation study, EURL ECVAM prepared a 4th SOP.

4. SOP "T-Screen assay using a QUANTITATIVE HIGH THROUGHPUT screening approach" v1.0 (used in Part 2 of the validation study

Contact information Method developer:

Arno Gutleb PhD, ERT Luxembourg Institute of Science and Technology (LIST) Environmental Research and Innovation (ERIN) Department 41, rue du Brill L-4422 Belvaux Grand-duchy of Luxembourg Tel: +352 275 888 481 e-mail: arno.gutleb@list.lu

EU-NETVAL facility

Joanna Roszak National Center for Alternative Methods to Toxicity Assessment (CMA) Department of Translational Research Nofer Institute of Occupational Medicine 91-348 Lodz, 8 Sw. Teresy St, POLAND e-mail: Joanna.Roszak@imp.lodz.pl https://www.imp.lodz.pl/krajowe-centrum-metod-alternatywnych-do-oceny-toksycznosci

EU Science Hub

https://joint-research-centre.ec.europa.eu

JRC133179

Ispra: European Commission, 2023 © European Union, 2023



The reuse policy of the European Commission documents is implemented by the Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Unless otherwise noted, the reuse of this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence (<u>https://creativecommons.org/licenses/by/4.0/</u>). This means that reuse is allowed provided appropriate credit is given and any changes are indicated.

For any use or reproduction of photos or other material that is not owned by the European Union, permission must be sought directly from the copyright holders. The European Union does not own the copyright in relation to the following elements: - Cover page illustration, © BioRender.com

How to cite this report: Roszak J., Standard Operating Procedure for Handling, Maintenance and Quality Control of the GH3 cell line version 2.0, applied in Part 2 of the EURL ECVAM thyroid validation study, European Commission, Ispra, 2023, JRC133179

1	Standard Operating Procedure
2	
3	Handling, Maintenance and Quality Control of the
4	GH3 cell line
5	
6	
7	Author: EU-NETVAL laboratory NIOM, Joanna Roszak
8 9	Version: 02 Date: 27.12.2021
10 11	
12	
13	
14	

15	Contents				
16	1. Scope of the SOP	3			
17	1.1 Safety				
18	1.2 Test System				
19	1.3 Apparatus and Materials				
20	1.4 Reagents and Chemicals	3			
21	2. Handling and Maintenance of Test System	5			
22	2.1. Stock solutions of reagents	5			
23	2.1.1. Ethanolamine [50 mM]	5			
24	2.1.2. Sodium selenite [50 μg/mL]	5			
25	2.1.3. Human apotransferrin [2 mg/mL]				
26	2.1.4. Bovine serum albumin [100 mg/mL]	5			
27	2.2. Media	5			
28	2.2.1. Cell culture medium (cDMEM/F12; completed cDMEM/F12)				
29	2.2.2. Cell cryopreservation medium	6			
30	2.2.3. PCM medium	6			
31	2.3. Maintenance and handling of GH3 cells	6			
32	2.3.1. Restoring GH3 cells				
33	2.3.2. Cryopreservation				
34	2.3.3. Quality control to be performed	7			
35	2.3.4. Detachment of GH3 cells				
36	2.3.5. Passaging of GH3 cells	8			
37	2.3.6. Determination of cell suspension density and cell viability	9			
38	2.4. Determination of the doubling time (Td) of GH3 cells	9			
39	2.5. Acceptance Criteria1	0			
40	3. Reference(s)1	1			
41	4. Change log1	2			
42					

43 **1.** Scope of the SOP

A rat pituitary tumour cell line (GH3) is the test system for T-screen assay. This Standard Operating Procedure describes how to handle and maintain the GH3 cells and the quality control to be performed. The GH3 cell line should fulfil acceptance criteria for absence of microbiological contamination and *Mycoplasma sp.* and the doubling time (Td).

48 **1.1** Safety

All activities related to the culture of GH3 cells (except for counting cells in Bürker chamber) should
 be performed under sterile conditions under a laminar chamber.

51 **1.2 Test System**

• GH3-cell line – a rat pituitary tumour cell line (ATCC[®] CCL-82.1[™])

53 **1.3** Apparatus and Materials

- Clean glass vials for the preparation of stock solutions (e.g. gas chromatography vials or
 Sarstedt #86.1509)
- 96-well microplates (e.g., Nunc # 167008)
- 57 Freezer below -16 °C
- 58 Freezer below -70 °C
- 59 Freezer below -135 °C or a liquid nitrogen tank
- 60 Refrigerator 2-10 °C
- CO₂ humidified incubator at 37°C +/- 2 °C, 5% CO₂ +/- 0.5%
- 62 37 °C water bath
- 63 Pipette Aid
- Pipettors (e.g. p1000-100, p100-10, p10-0.5)
- Centrifuge
- 66 Vacuum aspirator
- Sterile Laminar Flow Hood
- 68 Culture Flasks (T75, T25; e.g. Nunc, Falcon)
- Serological pipettes (1-2 mL, 5 mL, 10 mL, and 25 mL)
- Sterile, filter pipette tips (e.g. 10 μL, 200 μL, and 1000 μL)
- Sterile, pipette tips without filter (e.g. 10 μL, 200 μL, and 1000 μL)
- Conical tubes (5 mL, 15 mL, and 50 mL)
- Syringe filters (0.22 μm)
- 74 **1.4** Reagents and Chemicals
- Foetal calf/bovine serum (e.g. Gibco #10270106)
 Dulbecco's modified Eagle's medium/Ham's Nutrient Mixture F-12 (DMEM/F-12; 1:1 mixture with phenol red and HEPES (15 mM) (e.g. Sigma-Aldrich#D6421)
 DMEM/F-12 w/o L-Glutamine, with 15 mM HEPES and w/o phenol red (e.g. Sigma-Aldrich # D6434)
 UEDEC 1M achietien (e.g. Sigma Aldrich #U02027)
- HEPES 1M solution (e.g. Sigma-Aldrich #H0887)
- Penicillin-Streptomycin Solution (e.g. Sigma-Aldrich #P0781)

- Bovine insulin (e.g. Sigma-Aldrich #10516)
- Ethanolamine (e.g. Sigma-Aldrich #E0135)
- Sodium selenite (e.g. Sigma-Aldrich #S5261)
- Human apotransferrin (e.g. Sigma-Aldrich #T2036)
- Bovine serum albumin (e.g. Sigma-Aldrich #A9418)
- PBS without Ca²⁺/Mg²⁺ (e.g. Biological Industries #02-023-1A)
- Accutase (e.g. Sigma-Aldrich #A6964)
- Deionized water (dH₂O)
- 90 *Mycoplasma sp.* detection kit (e.g. MycoBlue Mycoplasma Detector; VAZYME# D101-01)

91 **2.** Handling and Maintenance of Test System

92 **2.1. Stock solutions of reagents**

93 **2.1.1.** Ethanolamine [50 mM]

Prepare a 50 mM stock solution of ethanolamine in dH_2O by diluting a pure ethanolamine (16.6 M)

- 95 332x, i.e. 10 μ L of ethanolamine (16.6 M) added to 3.310 mL of dH₂O, and filter (0.22 μ m pore size).
- 96 The stock should be prepared freshly before to use or stored at room temperature in closed glass
- 97 containers.

98 **2.1.2.** Sodium selenite [50 μg/mL]

- 99 Prepare 10x concentrated stock solution of sodium selenite (500 µg/mL) in dH₂O, then dilute it 10x
- 100 to receive the desired concentration, i.e. 50 μ g/mL. Filter stock solution (0.22 μ m pore size) and 101 store in alignets below 16 °C
- 101 store in aliquots below -16 °C.

102 **2.1.3.** Human apotransferrin [2 mg/mL]

Prepare the 2 mg/mL stock solution of human apotransferrin in dH2O, filter (0.22 μm pore size), and
 store in aliguots below -16 °C.

105 **2.1.4.** Bovine serum albumin [100 mg/mL]

- 107 store in aliquots at 2-8 °C.

108 **2.2. Media**

109 2.2.1. Cell culture medium (cDMEM/F12; completed cDMEM/F12)

- 110 Dulbecco's modified Eagle's medium/Ham's Nutrient Mixture F-12 (DMEM/F-12; 1:1 mixture; with
- 111 phenol red and 15 mM HEPES) supplemented with 10% Foetal calf serum, 2.5 mM L-Glutamine and
- 112 additional amount of HEPES to obtain 25 mM.
- 113 To prepare *cDMEM/F12* the following volume of supplements should be added:

	the final	
	concentration	Volume [mL]
DMEM/F-12 w/o L-Glutamine, with 15 mM HEPES		500
(e.g. Sigma-Aldrich #D6421)*		500
Heat inactivated FCS/FBS**	10%	57.6
200 mM L-Glutamine	2.5 mM	7.2
1 M HEPES	up to 25 mM	5.8
Penicillin-Streptomycin solution (100x)	llin-Streptomycin solution (100x) 1%	
Total	576.4	

114 *if different DMEM/F-12 is used the final concentration of HEPES and L-Glutamine should be

adjusted to 2.5 mM and 25 mM, respectively.

- 116 ** if heat-inactivated FCS/FBS was purchased, it should be defrost at 2-10°C e.g. during the night and
- 117 stored in aliquots at below -16°C.
- 118 If non-inactivated FCS/FBS was purchased, it should be heat-inactivated in water bath at 56-57°C for
- 119 $\,$ 30-35 min and filtered (0.2 $\mu m)$ before aliquoting.

120 2.2.2. Cell cryopreservation medium

- 121 Complete cell culture medium described in Section 2.1.1. supplemented with 5% (v/v) DMSO.
- 122 $\,$ $\,$ The volume of the freeze medium prepared depends on the amount of vials. To prepare 1 mL of the
- 123 $\,$ $\,$ freeze medium mix: 50 μL of DMSO with 950 μL of cDMEM/F12.

124 **2.2.3.** *PCM medium*

- 125 PCM medium is a Dulbecco's modified Eagle's medium/Ham's Nutrient Mixture F-12 (DMEM/F-12;
- 126 1:1 mixture) without phenol red supplemented with 10 µg/mL bovine insulin, 10 µM ethanolamine,
- 127 10 ng/mL sodium selenite, 10 μ g/mL human apotransferrin, 500 μ g/mL bovine serum albumin.
- 128 To prepare *PCM medium* the following volume of supplements should be added:

	Final concentration	Volume [mL]	
DMEM/F-12 w/o L-Glutamine, with 15 mM HEPES		500	
(e.g. Sigma-Aldrich # D6434)*		500	
200 mM L-Glutamine	2.5 mM	6.5	
1 M HEPES	up to 25 mM	5.2	
Penicillin-Streptomycin solution (100x)	1%	5.2	
10 mg/mL bovine insulin	10 μg/mL	0.523	
50 mM ethanolamine (Section 2.1.1)	10 μM	0.105	
50 μg/mL sodium selenite (Section 2.1.2)	10 ng/mL	0.105	
2 mg/mL human apotransferrin (Section 2.1.3)	10 μg/mL	2.6	
100 mg/mL bovine serum albumin (Section 2.1.4)	500 μg/mL	2.6	
Total		523.0	

129 *if different DMEM/F-12 is used the final concentration of HEPES and L-Glutamine should be

130 adjusted to 2.5 mM and 25 mM, respectively.

131 **2.3.** Maintenance and handling of GH3 cells

132 **2.3.1.** Restoring GH3 cells

133 a. Restoring a purchased vial of GH3 cells

- Thaw the GH3 cells (a purchased vial) according to the supplier's instructions, using the culture
 medium described in Section 2.1.1.
- 136 2. Seed at the cell density provided on the certificate of analysis.
- 137 3. Culture GH3 cells at 37 ± 1 °C and 5 ± 0.5% (v/v) CO₂ in a humid atmosphere in cDMEM/F12
 138 medium
- 139

140 **b.** Restoring GH3 cells frozen in the laboratory

- 141 1. Prepare a tube with 9 mL of cDMEM/F12 medium
- 142 2. Thaw the vial in a 37 ± 1°C water bath as rapidly as possible using gentle hand agitation.
 143 Immerse or spray the vial in 70% alcohol or relevant disinfectant to sterilize outside.
- 144 3. Unscrew the cap of the vial and transfer the contents of the vial to the pre-warmed medium in145 the tube.
- 146 4. Centrifuge 5 min 1500 rpm.
- 147 5. Discard the supernatant
- 148 6. Resuspend the pellet in the fresh warm cDMEM/F12 medium
- 149 7. Transfer all cells into a T25 flask, leaving a small portion of the cell suspension for counting
- 150 Culture GH3 cells at 37 ± 1 °C and $5 \pm 0.5\%$ (v/v) CO₂ in a humid atmosphere in cDMEM/F12 culture 151 medium.
- 152 Prepare both a Master Cell Bank (e.g. 10-20 vials) and Working Cell Bank (e.g. 20-30 vials).

153 2.3.2. *Cryopreservation*

- 154 General protocol of ATCC provides the following instructions:
- 155 Always harvest cells in exponential growth.
- Prepare a freeze medium consisting of complete culture medium and 5% DMSO (Section
 2.2.2). Do not add undiluted DMSO to a cell suspension as dissolution of DMSO in aqueous
 solutions gives off heat (exothermic).
- 1592. Label the appropriate number of vials with the name of the cell line and the date and thepassage number.
- 1613. Collect cells by gentle centrifugation (10 min at 125 x g) and resuspend them in the freeze162medium at a concentration of 1×10^6 to 7×10^6 viable cells/mL.
- 163 4. Add 1 mL of the cell suspension to each of the vials and seal.
- Allow cells to equilibrate in the freeze medium at room temperature for a minimum of 15
 minutes but no longer than 60. This time is usually taken up in dispensing aliquots of the cell
 suspension into the vials. After 60 minutes, cell viability may decline due to the DMSO.
- 167
 6. Place the vials into a controlled-rate freeze chamber, such as ATCC ACS-6000, CoolCell LX, and place the chamber in a -70°C (or colder) mechanical freezer for at least 24 hours.
 169
 169
 169 Alternately, use a programmable freezer unit set to cool the cryovials at -1°C per minute until a temperature below -70°C is achieved.
- 171 7. Quickly transfer the vials to a liquid nitrogen or a -130°C (or colder) freezer. Frozen material
 172 will warm up at a rate of 10°C per minute and cells will deteriorate rapidly if warmed above 173 50°C.
- 174 8. Record the location and details of the freeze.
- 175 After at least 24 hours at below -130°C, remove one cryovial, restore the cells in culture, and 176 determine their viability and sterility as described in Section 2.3.3.

177 **2.3.3.** Quality control to be performed

178 Before cryopreservation and after restoring the first cryovial of the cell bank; check your cell culture 179 for absence of microbiological contamination such as fungi, bacteria, yeast, which can be verified by

180 microscopic observation after 1-2 weeks culturing of the cells without antibiotics assuring proper

181 safety conditions or out-sourcing.

- 182 Before cryopreservation and during normal use, check your cell culture for *Mycoplasma sp.* 183 contamination using a PCR-based mycoplasma detection procedure or out-sourcing.
- 184 The culture that is contaminated (microscopic observation or a positive result in a mycoplasma 185 detection kit) should be disposed in accordance with the appropriate system procedure for the 186 disposal of hazardous wastes. A new frozen vial with the GH3 cells should be used for testing or for
- 187 multiplication and cryopreservation.

188 **2.3.4.** Detachment of GH3 cells

- 189 GH3 cells should be detached by using Accutase.
- 1901. View the GH3 culture using an inverted microscope to assess the degree of confluency and
confirm the absence of bacterial and fungal contaminants
- Remove spent medium and wash the cell monolayer with PBS without Ca²⁺/Mg²⁺ (5 mL/a
 T25 flask or 10 mL/a T75 flask)
- Pipette Accutase (RT) into the washed cell monolayer using 1-2 mL/T25 or 3-6 mL/T75.
 Gently rotate the flask to cover the monolayer with Accutase.
- 196 4. Return the flask to the incubator and leave for 3-5 minutes.
- 197 5. Examine the cells using an inverted microscope to ensure that all the cells are detached and
 198 floating. DO NOT tap or shake the flask to release any remaining attached cells since it
 199 increases cell mortality.
- 2006. Add fresh serum-containing medium (cDMEM/F12) to the cells to inactivate Accutase (5201mL/a T25 flask or 10 mL/a T75 flask). In some circumstances, i.e. detachment after202preincubation cells in PCM medium for T-screen test, the PCM medium must be used for203inactivation of Accutase by dilution.
- 204 7. Transfer the content to a new labeled vial and centrifuge the cells 1500 rpm; 3-5 min.
- Resuspend the pellet into a known volume of fresh medium cDMEM/F12 and count the cells
 using Trypan blue to determine density and viability as described in Section 2.3.6

207 2.3.5. Passaging of GH3 cells

- Passage GH3 cells in T25 or T75 tissue culture flasks every three-four days by using Accutase. Every
 two-three days culture medium should be exchanged with the fresh one.
- 210 1. Detach the GH3 cells as described in Section 2.3.4
- After determination of density and viability of GH3 cell suspension (Section 2.3.6) transfer an
 appropriate number of the viable cells into a new flask. Recommended number of cells to
 subculture in 3-4 days is:
- 214 6 x 10⁵ cells/T25 flask (5-7 x10⁵ cells/T25 flask) or,
 - 1.8 x 10⁶ cells/T75 flask (1.5-2.1 x 10⁶ cells/T75 flask)
- 216 Alternatively, if the cells cannot be counted, then a sub-cultivation ratio of 1:2 to 1:4 is 217 recommended
- 2183.Culture GH3 cells at 37 ± 1 °C and $5 \pm 0.5\%$ (v/v) CO2 in a humid atmosphere in culture219medium (Section 2.1.1)

220

221	2.3.6. Determination of cell suspension density and cell viability			
222	Density and vability of cell suspension is determined in Trypan blue exclusion test using Bürker			
223	3 chamber. To this end:			
224	 Take 100 μL representative sample of cell suspension into Eppendorf 			
225	- Add 100 μL Trypan Blue solution			
226	 Count cell number at least in 3 squares 			
227	- Calculate cell density [cells/mL] using a formula below:			
228	Cell density [cells/mL] = X/Y * Z *10000			
229	where,			
230	X= the sum of all cells (#) counted in the large squares (min. 3 max 9)			
231	Y = the number of the counted large squares			
232	Z = dilution in Trypan Blue solution (usually 2x)			
233	10000 = conversion factor to 1 mL			
234	(#) IMPORTANT! All cells means all viable cells or all/total cell number (viable+nonviable), depending			
235				
236	whereas for determination of the doubling time total number of cells is counted (density of			
237	viable+nonviable cells).			
238	 Calculate cell viability [cells/mL] using a formula below: 			
239	Viability [%] = X*100/(X+Y)			
240	where,			
241	X = number of viable cells (cells with clear cytoplasme) counted in the large			
242	squares (min. 3 max 9)			
243	Y = number of nonviable cells (cells with blue cytoplasme) counted in the			
244	same large squares as X has been counted			
245				

246 **2.4.** Determination of the doubling time (Td) of GH3 cells

247 Every time when the GH3 cells are restored the doubling time (Td) of GH3 culture should be 248 determined both in cDMEM/F-12 and PCM medium. To this end, an appropriate number of T25 249 flasks with the known number of cells will be set (5.5-6.5x10⁵ cells/T25) in cDMEM/F12 medium and 250 in PCM medium (the number of flasks depends on the number of time points; at least 6 time points 251 should be planned). The exact number of cells applied to the culture flasks will be given in the source 252 materials. The cells should be cultured for 10 days without changing medium and the total no. of 253 cells should be counted everyday (with exception of weekend). In every time point (e.g. every 24 h) 254 cells from one cell culture in cDMEM/F12 and one cell culture in PCM should be detached using 255 Accutase and total no. of cells (live and dead) should be counted.

256 Detachment of GH3 cells should be performed as described in Section 2.3.4 with one exception: 257 spent medium and PBS after washing should not be discarded but they should be collected in the 258 same vial with the cells.

- Determine density of cell suspension (total number of cells/viable+nonviable)using Trypan Blue asdescribed in Section 2.3.6
- 261 Doubling time (Td) should be calculated based on total number of cells in time point (live+dead) 262 according the following formula (ATCC, 2014):

$$Td = (t2 - t1) \times \frac{\log(2)}{\log(q2/q1)}$$

- where:
- t2-t1 incubation time in any units e.g. hours (the beginning of the incubation time the end of theincubation time)
- 267 q1- the cell number at the beginning of the incubation time
- 268 q2- the cell number at the end of the incubation time
- 269 It is recommended to start the measurement on Friday and calculate the Td based on results
- obtained in 72- and 96-h culture of the cells when the GH3 cell growth is exponential.

271 **2.5.** Acceptance Criteria

- 272 The GH3 cells can be used for the T-screen assay when:
- 273 1. Absence of mycoplasma is confirmed
- 274 2. Absence of microbiological contamination is confirmed
- 275 3. The doubling time of the GH3 cells in cDMEM/F12 medium is 42 ± 5h
- 276
 4. Cell number in PCM in 72h±1h and 96h±1h of culture should be at least 40% lower that cell number in cDMEM/F12, when determined simultaneously.

278	3.	Refe	rence(s)
279 280		1.	Characteristics of GH3 provided by The Global Bioresource Center (ATCC) https://www.lgcstandards-atcc.org/products/all/CCL-82.1.aspx?geo_country=pl#
281		2.	ENV/JM/MONO(2018)19: Guidance Document on Good In Vitro Method Practices
282			(GIVIMP, 2018)
283		3.	ATCC (2014), Animal Cell Culture Guide, ATCC.
284			https://www.atcc.org/~/media/PDFs/Culture%20Guides/AnimCellCulture_Guide.ashx.
285			
286			

287 4. Change log

- 288 Standard Operating Procedure:
- 289 Handling, Maintenance and Quality Control of the GH3 cell line

290

ID	Version	Status	Date	List of changes in version 02 with respect to version 01:
1.	v. 01	Approved	03.03.2021	not applicable
2.	v. 02	Draft	09.12.2021	- Revising section 2.1.1, 2.1.2, 2.3.1b and 2.3.4 p.6
3.	v. 02	Final	27.12.2021	- Adding a section: Change log

GETTING IN TOUCH WITH THE EU

In person

All over the European Union there are hundreds of Europe Direct centres. You can find the address of the centre nearest you online (<u>european-union.europa.eu/contact-eu/meet-us_en</u>).

On the phone or in writing

Europe Direct is a service that answers your questions about the European Union. You can contact this service:

- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls),
- at the following standard number: +32 22999696,
- via the following form: <u>european-union.europa.eu/contact-eu/write-us_en</u>.

FINDING INFORMATION ABOUT THE EU

Online

Information about the European Union in all the official languages of the EU is available on the Europa website (<u>european-union.europa.eu</u>).

EU publications

You can view or order EU publications at <u>op.europa.eu/en/publications</u>. Multiple copies of free publications can be obtained by contacting Europe Direct or your local documentation centre (<u>european-union.europa.eu/contact-eu/meet-us_en</u>).

EU law and related documents

For access to legal information from the EU, including all EU law since 1951 in all the official language versions, go to EUR-Lex (<u>eur-lex.europa.eu</u>).

Open data from the EU

The portal <u>data.europa.eu</u> provides access to open datasets from the EU institutions, bodies and agencies. These can be downloaded and reused for free, for both commercial and non-commercial purposes. The portal also provides access to a wealth of datasets from European countries.

The European Commission's science and knowledge service Joint Research Centre

JRC Mission

As the science and knowledge service of the European Commission, the Joint Research Centre's mission is to support EU policies with independent evidence throughout the whole policy cycle.



EU Science Hub joint-research-centre.ec.europa.eu

- @EU_ScienceHub
- **f** EU Science Hub Joint Research Centre
- in EU Science, Research and Innovation
- EU Science Hub
- O EU Science